Videos

John A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.

At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.

John J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.

Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.

Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema.

Mark J. Gallardo, MD, discusses how the laser performed alongside cataract surgery in open-angle glaucoma, including medication burden and safety.

Drew Carey, MD, and Andrew G. Lee, MD, discuss triage, visual fields, double vision, and cataract topics from Neuro-Ophthalmology Subspecialty Day.

At AAO 2026 Retina Subspecialty Day, SriniVas Sadda, MD, outlined limits of current GA growth metrics and introduced border advancement pace and a location-weighted GA severity score.

At EURETINA 2026, Mitrofanis Pavlidis, MD, PhD, explains how double-cutting probes, new pump technology and integrated visualisation reduced core vitrectomy time in 27-gauge surgery.

A handful of eye care providers spoke on the factors that have led to a lack of eye care access for World Sight Day.

Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.

At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.

Ali Tafreshi discusses Oku Digital Health, launched from Topcon to link eye care with primary care, and the barriers ahead.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

Host Deborah Ristvedt, DO, welcomes Dr. Mathews to discuss the relationships, passions, and intentional choices that have shaped her career as a cornea, cataract, and refractive surgeon, dry eye expert, and educator.

Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.

Ritesh Narula, MBBS, MS, discusses phase 1 and early phase 2 results of the Eyestem subretinal stem cell study in geographic atrophy, including an 11-letter mean visual acuity gain maintained at 18 months.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

João Pedro Marques, MD, MSc, PhD, FEBOphth, discusses the IRD-PT, a web-based Portuguese registry of roughly 2,400 patients with inherited retinal diseases that supports research and identifies patients for clinical trials.

At EURETINA 2026, Elon van Dijk, MD, PhD, FEBOphth, reviewed trial evidence favouring half-dose PDT over micropulse laser and eplerenone for central serous chorioretinopathy.

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model being built with 108 partners from more than 40 countries

Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment needs in DME, with early vision and anatomy gains and no significant safety signals.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews 2-year SPECTRA data on 4D-150 gene therapy for DMO and the phase 3 4SIGHT trial comparing it with aflibercept.

OT Roundup returns with MOGENRY's 4-year RP data, RCA's retina care report, SYD-101's FDA hearing, and new OCU410 GA data.

Francesca Cordeiro, PhD, MD, FRCOphth, explains how Detection of Apoptosing Retinal Cells (DARC) imaging predicted the speed and direction of GA growth and could help stratify patients for treatment.

For CVI Awareness Day, 3 experts explain why CVI can hide behind a normal eye exam and why early referral matters.

Cathleen McCabe, MD, presents real-world data from a 57-site US study of the enVista Aspire IOL at ESCRS 2026, reporting over 90% patient satisfaction and 20/32 uncorrected intermediate vision in more than 70% of patients.

Nimesh A. Patel, MD, explains why myopia-related retinal detachments are appearing earlier and how routine exams can catch them.